---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-081482"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:07:27.714882+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Onconetix effects 1:40 reverse stock split; Nasdaq delisting notice resolved via new listing approval

## Summary
- Reverse stock split at ratio 1:40 effective Sept. 24, 2024; no fractional shares issued, cash paid in lieu.
- Nasdaq delisting notice for bid price non-compliance received Sept. 18; mooted by Sept. 19 approval of new listing application meeting $4 closing bid price.
- Issued 142,749 shares to Veru upon conversion of Series A Preferred; 6,741,820 shares to former Proteomedix holders on Series B automatic conversion.
- Issued 513,424 units (share + warrant) to Altos plus 154,027 shares on warrant exercise; all exempt from registration.
- Post-split shares outstanding: 8,307,051 total (including 2,656 unvested restricted stock).

## SEC filing metadata
- accession: 0001213900-24-081482
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 3.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/0001213900-24-081482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea0215560-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-081482
- JSON: https://secwatch.observer/filing/0001213900-24-081482.json
- Plain text: https://secwatch.observer/filing/0001213900-24-081482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.